Ahmed Hamdan | Pharmaceutical and Clinical Sciences | Research Excellence Award

Dr. Ahmed Hamdan | Pharmaceutical and Clinical Sciences | Research Excellence Award

University of Tabuk | Saudi Arabia

Dr. Ahmed Mohsen Elsaid Hamdan is an Assistant Professor in the Department of Pharmacology and Toxicology at the University of Tabuk, with more than 14 years of academic and research experience in pharmaceutical sciences. His research is centered on chronopharmacology, chronotherapeutics, and smart drug delivery systems, with a strong translational focus on neurological and neurodevelopmental disorders. His work aims to elucidate how biological rhythms and circadian regulation influence drug efficacy, toxicity, and disease progression. A major theme of Dr. Hamdan’s research is the development of evidence-based non-pharmacological and nutritional therapeutic strategies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, as well as neurodevelopmental disorders including autism spectrum disorder and ADHD. He extensively investigates phytochemicals, probiotics (particularly Lactobacillus species), and nutraceuticals, emphasizing the gut–microbiome–brain axis as a key mechanistic pathway. His studies integrate pharmacological, behavioral, biochemical, and molecular approaches to identify novel therapeutic targets and mechanisms. In parallel, Dr. Hamdan has contributed significantly to advanced nano- and smart drug delivery systems for cancer therapy, dermatological disorders, infectious diseases, and chronic inflammatory conditions, enhancing drug bioavailability and therapeutic outcomes. His research portfolio also includes hepatoprotective and cardioprotective strategies and chronopharmacological exploration of natural products. Dr. Hamdan has published 105 peer-reviewed articles, with the majority appearing in high-impact Q1–Q2 journals, and holds an h-index of 26. He has secured 13 competitive research grants, is involved in an ongoing patent, and maintains active collaborations with national and international institutions, reflecting his strong commitment to innovative and multidisciplinary biomedical research.

Citation Metrics (Scopus)

1300
900
500
100
    0

Citations
1,047

Documents
69

h-index
19

Citations

Documents

h-index


View Scopus Profile View ORCID Profile View Google Scholar Profile

Featured Publications

Rolf Teschke | Precision Medicine | Best Academic Researcher Award

Prof. Rolf Teschke | Precision Medicine | Best Academic Researcher Award

Prof. Rolf Teschke | Klinikum Hanau | Germany

Rolf Teschke, M.D., Professor of Medicine, is a distinguished German physician and internationally recognized expert in gastroenterology, hepatology, and the complex mechanisms of hepatotoxicity. Born in Gera, he pursued medical studies at the universities of Munich and Marburg, earning his medical degree and completing his inaugural thesis. His early scientific foundation was shaped in pathology, where his interest in liver injury and toxic mechanisms first took root. A pivotal stage of his career unfolded in New York, where he worked under the mentorship of renowned liver specialist Charles S. Lieber. During this period, he conducted influential biochemical research on alcohol-related liver injury, including solubilizing and isolating the microsomal ethanol-oxidizing system and exploring cytochrome P450–related pathways. This work strengthened his commitment to uncovering the biological foundations of hepatotoxicity and decisively shaped his future research direction. Returning to Germany, Professor Teschke continued to advance academically in gastroenterology, hepatology, and infectious diseases at the Heinrich Heine University of Düsseldorf. He completed his habilitation, received a prestigious university research award, and expanded his clinical and experimental work on alcohol-induced liver damage, hydrocarbon toxicity, and the growing challenge of drug-induced liver injury. As a department director at a major teaching hospital, he further deepened his focus on drug-induced liver injury, contributing significantly to the development and refinement of the RUCAM causality assessment method in collaboration with international experts. His scholarly output is substantial, consisting of more than 250 English-language publications, including books and book chapters. His work has earned 6,890 citations across 4,042 documents, with an h-index of 48, reflecting his strong influence in the global hepatology community. He has served as associate editor of Annals of Hepatology and held editorial roles across numerous leading medical and scientific journals.

Profile; Scopus | Orcid | Research Gate

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Ahsan Khan | Biomedical Engineering | Research Excellence Award

Dr. Ahsan Khan | Biomedical Engineering | Research Excellence Award

Dr. Ahsan Khan | Tongji University | China

Dr. Ahsan Riaz Khan is an accomplished researcher specializing in chemical engineering, environmental sciences, corrosion science, surface engineering, and biomaterials. He holds advanced academic qualifications in Chemical Engineering and Environmental Sciences, complemented by strong interdisciplinary training across materials development, environmental health, and biomedical applications. He is currently serving as a Postdoctoral Researcher at the School of Medicine, Tongji University, Shanghai, where he contributes to cutting-edge research on biomaterials, corrosion-resistant surfaces, biocompatibility, drug-release systems, and in-vivo/in-vitro implant evaluations. Dr. Khan’s research expertise spans the development of novel, sustainable, and cost-effective coating materials; surface modification of metals and alloys; tribology; anticorrosion technology; adhesion engineering; electrochemical methods; and advanced techniques in cell culture, toxicity analysis, and immunohistochemistry. His interdisciplinary background enables him to work at the intersection of engineering, materials science, medicine, and environmental sustainability. He has published 28 peer-reviewed research papers, contributing significantly to high-impact journals in materials science, corrosion protection, biomaterials, environmental pollution, electrochemistry, and regenerative medicine. His publications have received over 330 citations with an H-index above 10, reflecting strong academic influence and global research engagement. His work includes notable contributions to magnesium alloys, smart scaffolds, hybrid biomaterials, environmental risk assessments, supercapacitive materials, and psychological health investigations. Dr. Khan has earned multiple academic honors, including innovation awards, competitive scholarships, excellence certificates, and internship recognitions. He has participated in a wide range of international conferences, workshops, and training programs in environmental management, materials engineering, GIS, chemical engineering, and waste management. Skilled in a broad array of analytical and characterization techniques—such as SEM, TEM, XPS, XRD, TGA, ICP-OES, GC-MS, Raman spectroscopy, and electrochemical workstations—Dr. Khan combines technical depth with strong research leadership. Fluent in English, Urdu, and conversational Chinese (HSK-3), he remains committed to advancing global research in materials innovation, corrosion engineering, environmental sustainability, and biomedical technology.

Profile: Google Scholar

Featured Publications

Khan, A. R., Grewal, N. S., Zhou, C., Yuan, K., Zhang, H. J., & Jun, Z. Recent advances in biodegradable metals for implant applications: Exploring in vivo and in vitro responses. Results in Engineering, 20, 101526.

Zafar, Z., Mehmood, M. S., Ahamad, M. I., Chudhary, A., Abbas, N., Khan, A. R., … Trend analysis of the decadal variations of water bodies and land use/land cover through MODIS imagery: An in-depth study from Gilgit-Baltistan, Pakistan. Water Supply, 21(2), 927–940.

Rehman, A. U., Shah, M. Z., Ali, A., Zhao, T., Shah, R., Ullah, I., Bilal, H., Khan, A. R., … Thermochemical heat storage ability of ZnSO₄·7H₂O as potential long-term heat storage material. International Journal of Energy Research, 45(3), 4746–4754.

Khan, M., Tiehu, L., Hussain, A., Raza, A., Zada, A., Alei, D., Khan, A. R., Ali, R., … Physiochemical evaluations, mechanical attenuations and thermal stability of graphene nanosheets and functionalized nanodiamonds loaded pitch-derived carbon foam composites. Diamond and Related Materials, 126, 109077.

Khan, Z. U., Razzaq, A., Khan, A., Rehman, N. U., Khan, H., Khan, T., Khan, A. U., … Physicochemical characterizations and pharmacokinetic evaluation of pentazocine solid lipid nanoparticles against inflammatory pain model. Pharmaceutics, 14(2), 409.

Diane Harper | Precision Medicine | Distinguished Scientist Award

Prof. Dr Diane Harper | Precision Medicine | Distinguished Scientist Award

Prof. Dr Diane Harper | University of MIchigan | United States

Prof. Dr. Diane M. Harper is a globally recognized physician-scientist, educator, and leader in women’s health, family medicine, and preventive oncology. She earned her SB and SM degrees in Chemical Engineering and Polymerics from the Massachusetts Institute of Technology (MIT), followed by her MD and MPH in Biostatistics/Epidemiology from the University of Kansas Medical School. Complementing her medical and public health expertise, she completed numerous prestigious postgraduate fellowships and executive leadership programs, including the Executive Leadership in Academic Medicine (ELAM) Program, University of Michigan Ross School of Business Leadership Development, and US PHS Primary Care Fellowship in Washington, D.C. Over her distinguished career, Dr. Harper has held senior academic and administrative appointments at leading institutions including Dartmouth College, University of Missouri–Kansas City, University of Louisville, and currently the University of Michigan, where she serves as a Professor of Family Medicine, Obstetrics and Gynecology, and Women’s and Gender Studies, and Affiliate Faculty in Biomedical Engineering. Her interdisciplinary expertise bridges medicine, engineering, and public health to improve women’s health outcomes worldwide. Internationally acclaimed for her pioneering work on Human Papillomavirus (HPV) and cervical cancer prevention, Dr. Harper has been instrumental in the development and clinical validation of HPV vaccines, advancing screening technologies, and establishing evidence-based guidelines for HPV-associated disease management. Her research spans clinical trials, shared decision-making, health equity, and policy reform, emphasizing underserved and physically disabled populations.

Profiles: Google Scholar

Featured Publications

Quinn, J. A., Munoz, F. M., Gonik, B., Frau, L., Cutland, C., Mallett-Moore, T., … & Harper, D. M. (2016). Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 34(49), 6047–6056.

Harper, D. M., DeMars, L. R. (2017). HPV vaccines – A review of the first decade. Gynecologic Oncology, 146(1), 196–204.

Tota, J. E., Struyf, F., Merikukka, M., Gonzalez, P., Kreimer, A. R., Bi, D., … & Harper, D. M. (2017). Evaluation of type replacement following HPV16/18 vaccination: pooled analysis of two randomized trials. Journal of the National Cancer Institute, 109(7), djw300.

Gorin, S. S., Jimbo, M., Heizelman, R., Harmes, K. M., & Harper, D. M. (2021). The future of cancer screening after COVID‐19 may be at home. Wiley Periodicals, Inc.

Dykens, J. A., Peterson, C. E., Holt, H. K., & Harper, D. M. (2023). Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally. Frontiers in Public Health, 11, 1067299.

FURONG LI | Medical Discoveries | Outstanding Scientist Award

Dr. FURONG LI | Medical Discoveries | Outstanding Scientist Award

Dr. FURONG LI, Shenzhen People’s Hospital, China

Dr. Fu-Rong Li, MD, PhD, is the Director of the Translational Medicine Collaborative Innovation Center at the First Affiliated Hospital (Shenzhen People’s Hospital) of the Southern University of Science and Technology, China. With a prolific academic background in clinical medicine, parasitology, and molecular biology, Dr. Li has made significant contributions in stem cell research, cancer immunotherapy, nanomedicine, and regenerative medicine. Over the course of his distinguished career, he has authored more than 80 peer-reviewed papers and holds several national patents. His pioneering work continues to influence the fields of translational and precision medicine both nationally and internationally.

🧬 Early Academic Pursuits

Dr. Fu-Rong Li embarked on his medical journey with an M.D. from Ningxia Medical College in 1984, followed by a Master’s degree in Parasitic Diseases with a focus on hydatidosis at Lanzhou Medical College in 1991. His academic dedication culminated in a Ph.D. in Molecular and Immune Parasitology from Tongji Medical University in 1999. These formative years laid the groundwork for his enduring contributions to translational medicine, immunotherapy, and stem cell biology. His research curiosity took root early, especially in the intersection of infectious diseases and immune response, which later evolved into a lifelong dedication to stem cell differentiation, regenerative medicine, and cancer immunotherapy.

🏥 Professional Endeavors

Dr. Li currently serves as the Director of the Translational Medicine Collaborative Innovation Center at Shenzhen People’s Hospital, affiliated with the Southern University of Science and Technology (SUSTech). Since 1999, he has held progressive roles from Assistant Professor to Professor, contributing significantly to the evolution of translational medicine in China. His early career included a stint as an Attending Physician in the Department of Digestive Medicine at Ningxia Medical University (1984–1988), followed by senior research and teaching roles at Lanzhou University’s Hydatid Research Laboratory. His professional trajectory showcases his dual capabilities in clinical practice and cutting-edge biomedical research.

🔬 Research Focus and Contributions

Dr. Li is internationally recognized for his pioneering work in stem cell biology, regenerative therapies, cancer diagnostics, and nanomedicine. His research contributions are vast, with over 85 peer-reviewed publications, covering topics like:

  • Differentiation of human induced pluripotent stem cells (iPSCs) into pancreatic β cells.

  • Cancer proteomics and exosomal signaling in lung adenocarcinoma.

  • Nano-immunodiagnostic tools for infectious and oncological diseases.

  • Single-cell analysis of non-coding RNAs in stem cell differentiation and immunity.

  • Development of novel multi-omics frameworks for understanding tumor biology.

His work has been published in prestigious journals such as Stem Cell Research & Therapy, Advanced Science, Cell Death & Disease, and NPJ Genomic Medicine.

🧪 Innovation and Patents

Dr. Li holds nine Chinese national invention patents, reflecting his commitment to translational applications of research. His inventions include:

  • Methods for iPSC to pancreatic cell differentiation via miRNAs.

  • Novel liquid chip-based miRNA detection kits.

  • Dual-labeled gold nanoprobes for diagnostic purposes.

  • Preparation methods for nano-magnetic drug microspheres.

These patents highlight his role as a scientific innovator and entrepreneurial researcher, bridging laboratory discoveries with real-world applications.

🏆 Accolades and Recognition

Dr. Li’s research excellence has earned him national and institutional recognition, especially for his work on diabetic wound healing, tumor immunotherapy, and stem cell engineering. His research has contributed to clinical advancements in personalized medicine and biomaterial-assisted stem cell therapy. He is frequently invited to speak at international conferences, reflecting his status as a leading expert in translational medicine and regenerative biology in China and beyond.

🌍 Impact and Influence

Through mentoring emerging scientists, supervising graduate students, and leading interdisciplinary collaborations, Dr. Li has cultivated a strong academic legacy. He is a bridge between fundamental biology and clinical medicine, influencing drug delivery systems, immunotherapy protocols, and biosensing platforms used globally. His work in lung cancer biology, in particular, has offered insights into cancer metastasis, immune checkpoint modulation, and exosome-mediated signaling pathways—laying the foundation for next-generation immunotherapies.

🔭 Legacy and Future Contributions

As a respected leader in Shenzhen’s biomedical ecosystem, Dr. Fu-Rong Li continues to shape the future of regenerative medicine, nanotechnology, and translational diagnostics. With over four decades of combined clinical and research expertise, he remains committed to advancing therapies for diabetes, cancer, and immune diseases. Looking ahead, Dr. Li is expected to contribute significantly to the integration of AI, single-cell sequencing, and precision medicine for real-time diagnostics and personalized treatment. His multidisciplinary approach ensures that his legacy will influence generations of scientists and physicians to come.

✍️Notable Publications

SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation

Author:  Haojie Yan , Qian He, Yubiao Gao, Xiaomei He, Haitao Luo, Lijuan Shao, Jun Dong, Furong Li

Journal: International Journal of Oncology .,

Year: 2025

Plant-Derived Extracellular Vesicles as Potential Emerging Tools for Cancer Therapeutics

Author: Lin DingChih-Jung ChangMin-Li LiangKang-Mei DongFu-Rong Li

Journal: Advanced Therapeutics

Year: 2024

Novel DNA Biosensing Platform for Detecting HIV Integrase for Highly Sensitive and Quantitative HIV Detection, Diagnosis, and Therapeutic Monitoring

Author:  Fuming Chen, Jing Wang, Jie Ma, Li Song, Haojie Yan, Feng Wang, Zhengrong Yang, Furong Li

Haishan Jiang | Medical Discoveries | Innovation in Science Award

Dr. Haishan Jiang | Medical Discoveries | Innovation in Science Award 

Dr. Haishan Jiang, Southern Medical University, China

Dr. Haishan Jiang, Chief Physician and Associate Professor at Southern Medical University’s Nanfang Hospital, is a leading expert in neurology, specializing in myopathy, peripheral neuropathy, and rare neurological diseases. As Deputy Director of the Neurology Department and head of the Myopathy and Peripheral Neuropathy subspecialty, he has pioneered gene therapies for SMA and ALS in South China. His research focuses on motor neuron and mitochondrial diseases, as well as gene therapy for rare conditions. Widely recognized, Dr. Jiang has been honored as the “Good Doctor of Guangzhou” and ranks top nationally in physician recommendations for multiple rare diseases.

Author Profile

ORCID

🧑‍🎓 Early Academic Pursuits

Dr. Haishan Jiang embarked on his medical journey with a deep-rooted commitment to understanding the complexities of the human nervous system. With a Doctor of Medicine degree and solid academic grounding, he demonstrated early on a keen interest in neurology, particularly in the areas of myopathy and peripheral neuropathy. His academic path was marked by diligence, a sharp scientific mind, and a profound dedication to uncovering the underlying mechanisms of rare neurological diseases. As a postgraduate supervisor, Dr. Jiang has also shown a strong passion for nurturing the next generation of medical professionals, sharing his knowledge and guiding their research pursuits with patience and precision.

🩺 Professional Endeavors

Currently serving at Nanfang Hospital of Southern Medical University, Dr. Jiang holds several key positions: Chief Physician, Associate Professor, Deputy Director of the Neurology Department, Director of Teaching, and Head of the Myopathy and Peripheral Neuropathy subspecialty. His clinical expertise spans a wide spectrum of neurological disorders, with a particular emphasis on difficult and rare conditions such as motor neuron disease (ALS), mitochondrial encephalomyopathy, and adult-onset spinal muscular atrophy (SMA). Dr. Jiang’s commitment to clinical excellence has led him to establish and lead the Guangdong Province Myopathy and Peripheral Nerve Specialized Alliance, a network aimed at advancing diagnosis, treatment, and research collaboration. Under his leadership, the department ranks among the top two nationally in terms of annual muscle and nerve biopsy volume, solidifying its reputation as a hub for neuromuscular disease care.

🧬 Contributions and Research Focus

Dr. Jiang’s research interests are firmly rooted in neurogenetic disorders, particularly motor neuron diseases (ALS) and mitochondrial disorders. His work seamlessly blends basic science with clinical application, focusing on understanding disease mechanisms and exploring cutting-edge gene therapy approaches. He has spearheaded some of South China’s most advanced gene therapy trials, including the region’s first gene therapy for adult SMA—the fourth such case in the country—and the first ALS gene therapy clinical trial in South China, also the second nationwide. His pioneering research not only contributes to academic knowledge but also offers hope to patients battling previously untreatable conditions. Through his clinical studies, Dr. Jiang is pushing the frontiers of personalized medicine, bringing precision diagnostics and therapy into the mainstream for rare and complex neurological diseases.

🏅 Accolades and Recognition

Dr. Haishan Jiang’s unwavering dedication to medical science and patient care has earned him widespread acclaim. Notably, he was honored as the sixth “Good Doctor of Guangzhou” and selected as part of the ninth batch of “Outstanding Provincial and Municipal Talents Supporting Xinjiang”, a testament to both his clinical excellence and humanitarian spirit. Furthermore, he was recognized by the Good Doctor Network as an “Annual Good Doctor” for his exceptional service in rare disease diagnosis and treatment. His reputation as a leading clinician is reflected in his top rankings in national physician recommendation lists—first place for 13 diseases, including ALS and mitochondrial encephalomyopathy, and second place for 15 others. These accolades not only highlight his expertise but also the trust he has earned from patients and peers alike.

🌍 Impact and Influence

Dr. Jiang’s work has had a transformative impact on neurology in China, particularly in the realm of rare diseases. By advancing the use of gene therapy and establishing regional alliances, he has created a robust infrastructure for collaboration, research, and clinical care. His contributions have significantly improved diagnostic timelines and therapeutic options for patients who previously faced long diagnostic odysseys and limited treatment possibilities. As a teacher and mentor, Dr. Jiang has shaped the careers of countless postgraduate students and young doctors, many of whom now contribute to clinical neurology and research across the country. His influence extends beyond the clinic to policy and advocacy, where he is a strong voice for the rare disease community.

🔬 Legacy and Future Contributions

Dr. Haishan Jiang stands at the forefront of a new era in neurology, where genomics and personalized medicine are reshaping how we understand and treat complex diseases. His legacy is already evident in the systems he has built, the patients he has helped, and the students he has inspired. Looking ahead, Dr. Jiang aims to further expand gene therapy applications, develop innovative treatment protocols, and foster international collaboration in rare disease research. With his continued focus on combining scientific rigor with compassionate care, Dr. Jiang is set to leave a lasting legacy in Chinese and global neurology. His work is not only rewriting the medical narrative for patients with rare conditions but also paving the way for future breakthroughs in neuroscience.

✍️ Publication Top Notes


📘A Multicenter Study of Hereditary Transthyretin Amyloidosis in China

Author: Xujun Chu; Juan Kang; Jingwen Xu; Haishan Jiang; Zhi‐Ying Wu; Qingping Wang; Wei Li; Jia Li;
Journal: Annals of Neurology
Year:2025

📘Knockdown of OPTN modulates miRNA-125b-5p expression via NF-κB pathways in amyotrophic lateral sclerosis

Author: Jian Qin; Ye He; Weiyi Yu; Zhaoyong Zhang; Xiaodan Chen; Yafang Hu; Haishan Jiang
Journal: Archives of Biochemistry and Biophysics
Year: 2025

📘Clinical features of hereditary transthyretin amyloidosis-polyneuropathy with transthyretin Ala97Ser(p.Ala117Ser) mutation in South Mainland China

Author: Yeli Zhu; Jingxian Fan; Xiying Zhu; Wei Li; Zhaoyong Zhang; Hui Zheng; Zhihua Zhou; Lingchao Meng; Ruxu Zhang; Haishan Jiang
Journal: Orphanet Journal of Rare Diseases
Year: 2025